Clinically Meaningful Improvements With Vibegron in Men With Overactive Bladder and Benign Prostatic Hyperplasia: A Responder Analysis of the Phase 3 COURAGE Trial
In this post hoc responder analysis from the phase 3 COURAGE trial, participants receiving vibegron vs placebo achieved clinically relevant reductions in bothersome OAB symptoms, as well as improvements in IPSS and OAB-q scores.
Authors
- Kenneth M. Peters
- David Staskin (ORCID: https://orcid.org/0000-0003-4972-765X)
- Salim Mujais
- Janet Owens‐Grillo (ORCID: https://orcid.org/0009-0003-2457-2214)
- Elizabeth Thomas (ORCID: https://orcid.org/0000-0002-5224-1119)
- Eric S. Rovner
Institutions
- Tufts University (US)
- Medical University of South Carolina (US)
- Sumitomo Dainippon Pharma (United States) (US)
Publication Details
- Journal
- Urology
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1016/j.urology.2025.08.051
- Primary Topic
- Urinary Bladder and Prostate Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00